Preparation and characterization of protein C-loaded PLA nanoparticles

Zambaux, M. F.; Bonneaux, F.; Gref, Ruxandra; Dellacherie, Édith; Vigneron, C.

doi:10.1016/s0168-3659(99)00073-5

Cited by 207 publications

(130 citation statements)

References 18 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…112 Each nanoparticle formulation of protein is unique and requires specific adaptation and evaluation. Improved protein stability was achieved by altering preparation processes, 113 by changing polymer/copolymer, 105,114 by changing or mixing solvents, 49,113 by adding protective additives 110,111 such as hydrophilic polymers (PEG 115,116 ), surfactants (poloxamer 188 104,117 ), pro-teins (serum albumin, 118 gelatin 105 ), cyclodextrins 118,119 to the inner aqueous phase. Such formulation optimizations permitted sustained release of active protein over several weeks in vitro.…”

Section: Drug Loadingmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

Section: Drug Loadingmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

show abstract

“…Among the method for preparation of PLGA particles, the emulsification-solvent evaporation is the most frequently employed one [19]. The water/oil/water (W/O/W) double emulsion technique has been successfully developed and used to incorporate hydrophilic molecules such as hydrophilic drugs, proteins and nucleotide into the lumen of biodegradable particles [20][21][22][23].…”

mentioning

confidence: 99%

Preparation and cellular uptake of PLGA particles loaded with lamivudine

et al. 2012

View full text Add to dashboard Cite

Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles loaded with lamivudine and coated with bovine serum albumin (BSA) were prepared via a double emulsion method. The influences of experiments parameters such as volume of inner aqueous phase, concentration of organic phase and ultrasonication time on the particle size and drug entrapment efficiency were investigated, obtaining PLGA particles with a diameter of ~260 nm and drug entrapment efficiency of ~35%. The particles were observed by scanning electron microscopy and transmittance electron microscopy, showing a core-shell structure. BCA assay found that 58 mg BSA was present on/in 1 g LPB particles. The loaded lamivudine showed a burst release at beginning and sustained release until 24 h in physiological conditions. Low pH could accelerate the release of lamivudine from PLGA particles, making the PLGA particles potential intelligent intracellular drug carriers. The PLGA particles were readily internalized into the human liver cells within a short time and increased gradually with the prolongation of incubation time regardless of the loading of lamivudine. The particles either resided within lysosomes or transferred to cytoplasm, but could not enter into the cell nucleus. The cell viability was not significantly influenced in the presence of the particles regardless of lamivudine encapsulation, suggesting that this kind of particles may be a good candidate for the intracellular anti-hepatitis B drug delivery.PLGA, lamivudine, cell uptake, intracellular distribution, drug delivery Citation:Wang B, Chen G Q, Mao Z W, et al. Preparation and cellular uptake of PLGA particles loaded with lamivudine.

show abstract

“…Endogenous Apelin and Protein C [2,[27][28][29] ]: Apelin hinders the progression of diabetes nephropathy. Apelin stimulates diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome.…”

Section: Specific: Specific Inhibitor Nox 4 Isoformmentioning

confidence: 99%

Biodegradable Nanoparticles for Delivering Drugs and Silencing Multiple Genes or Gene activation in Diabetic Nephropathy

Soni¹

2017

IJLSSR

View full text Add to dashboard Cite

ABSTRACT-Dialysis is the only mode of available palliative therapeutic modality to patient with end stage of renal disease. Diabetes is one of the foremost common causes of chronic renal disease and affecting large number of diabetic patients. By many theory, hypothesis and study are carried to understand the pathogenesis of Diabetic kidney disease or complication of diabetes i.e. diabetic nephropathy (DN) and based on pathophysiology many drugs and molecules are being developed targeting enzymes, intracellular proteins, micro RNA, Receptor, channel etc. Genes (like NFE2L2, HD1, RPD3 etc.) responsible for synthesis of transcription factor, proteins, enzymes and cytokine factors, intracellular antioxidant factor all play vital role in pathophysiology of DN. Targeting multiple genes, which play important role in pathophysiology of DN with nanoparticle loaded with siRNA or drugs or combination will not only reduce multiple drug and medication burden but also mitigate the disease faster and with reversal of pathological changes with safety, if the challenges are met. It is possible to target multiple genes, which play vital role in fibrosis and extracellular matrix expansion which are key features of DN with biodegradable particle. Each drug by unique mechanism specifically targeting protein, enzymes, receptor, channel etc. mitigates the progress of DN and multiple drugs are needed to inhibit the various mechanism. The approach of silencing the multiple genes or delivering drugs inside the cell organelles with biodegradable nanoparticles is novel, versatile and target specific to inhibit the progress of DN and to reverse the pathological changes efficiently as compared to drugs/molecules, if challenges of nanoparticle formulation are met. Based on the research till date and available resource suggest it is possible to target multiple genes or protein or enzymes or signaling molecules using biodegradable and biocompatible nanoparticles (NP) loaded with siRNA and drugs or combination of drug and siRNA.

show abstract

Preparation and characterization of protein C-loaded PLA nanoparticles

Cited by 207 publications

References 18 publications

Drug transport to brain with targeted nanoparticles

Drug transport to brain with targeted nanoparticles

Preparation and cellular uptake of PLGA particles loaded with lamivudine

Biodegradable Nanoparticles for Delivering Drugs and Silencing Multiple Genes or Gene activation in Diabetic Nephropathy

Contact Info

Product

Resources

About